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Alzheimer’s disease (AD) is a multifactorial pathology causing common brain spectrum
disorders in affected patients. These mixed neurological disorders not only include
structural AD brain changes but also cerebrovascular lesions. The main aim of the
present issue is to find the factors shared by the two pathologies. The decrease of
ubiquitin C-terminal hydrolase L1 (Uch-L1), a major neuronal enzyme involved in the
elimination of misfolded proteins, was observed in ischemic injury as well as in AD, but
its role in the pathogenesis of AD is far to be clear. In this study we demonstrated that
Uch-L1 inhibition induces BACE1 up-regulation and increases neuronal and apoptotic
cell death in control as well as in transgenic AD mouse model subjected to Bengal
Rose, a light-sensitive dye inducing that induces a cortical infarction through photo-
activation. Under the same conditions we also found a significant activation of NF-κB.
Thus, the restoration of Uch-L1 was able to completely prevent both the increase in
BACE1 protein levels and the amount of cell death. Our data suggest that the Uch-L1-
mediated BACE1 up-regulation could be an important mechanism responsible for Aβ
peptides accumulation in vascular injury and indicate that the modulation of the activity
of this enzyme could provide new therapeutic strategies in AD.
Keywords: Alzheimer’s disease, amyloid beta, mixed dementia, Uch-L1, BACE1
INTRODUCTION
Although
Q6
Alzheimer’s disease (AD) is considered a neurodegenerative disease evidence-based
pathology and epidemiology studies associate it with a vascular disease (Grammas et al., 2011).
Thus, vascular damage is often present in patients diagnosed with AD and mixed dementia
and it is significant factor in 10%–20% of cases (Schneider et al., 2007; Kapasi and Schneider,
2016). Epidemiological evidence also suggests that mixed AD and vascular diseases are reported
to be common in older adults where AD and vascular dementia share symptomatic, pathological
and neurochemical characteristics (Santos et al., 2017). Some authors have recently developed
the ‘‘vascular hypothesis of AD’’, according to which vascular damage would be responsible for
neurodegeneration. Studies supporting this theory show that vascular damage induces inefficient
cerebral clearance of Aβ, causing its accumulation in the parenchyma and blood vessel (Snyder
et al., 2015; Janota et al., 2016).
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Recently, we showed that Aβ 42 inhibits the activity of
ubiquitin C-terminal hydrolase L1 (Uch-L1). This event is related
to an up-regulation of BACE1, mediated by the activation of
NF-κB pathway as well as by an impairment of its lysosomal
degradation (Guglielmotto et al., 2012).
Uch-L1 is a neuronal enzyme representing 1%–2% of the
total brain proteins (Wilkinson et al., 1989). Uch-L1 function is
to remove ubiquitin from proteins that need to be directed to
proteasome pathway (Gong and Leznik, 2007).
It has been suggested that its role is particularly important
in removing excess, oxidized or misfolded proteins both in
physiology and pathology.
Thus, down-regulation of Uch-L1 induces the aggregation of
ubiquitinated proteins and promotes cell death in neurons. The
decrease of this enzyme was observed in both ischemic injury
and AD (Wang et al., 2017), but the role of this decrease in the
pathogenesis of the diseases is far to be clear.
Of note, some authors report that the activity of Uch-L1 is
lower in AD brain (Pasinetti, 2001; Choi et al., 2004) and its
levels are inversely proportional to the number of neurofibrillary
tangles (NFT) in sporadic AD brain patients (Chen et al.,
2013). Then, gracile axonal dystrophy mice that did not express
Uch-L1 have high levels of Aβ (Ichihara et al., 1995) and
in a double transgenic AD mouse model the Uch-L1 activity
was found diminished (Gong et al., 2006). Proteomics analysis
indicated that the level of Uch-L1 was lower in AD hippocampal
proteome (Sultana et al., 2007). Immunohistochemical studies
showed that Uch-L1 is associated with NFT and the reduction
of soluble Uch-L1 was inversely proportional to the number
of NFT in AD brains (Choi et al., 2004; Chen et al., 2013).
Moreover, Minjarez et al. (2013) identified that the NFT derived
from AD brains contained Uch-L1 component and proved the
colocalization of Uch-L1 and hyperphosphorylated Tau protein
in NFT.
In this study we demonstrated that the inhibition of Uch-L1
induces BACE1 up-regulation and increases neuronal cell
death in control as well as in AD transgenic mouse models
subjected to Bengal Rose, a light-sensitive dye inducing a cortical
infarction through photo-activation. Our data suggest that the
Uch-L1-mediated BACE1 up-regulation could be an important
mechanism for Aβ peptides accumulation both in AD and
cerebrovascular lesions.
MATERIALS AND METHODS
Animals
Two-month-old no carrier (control mice) and
B6SJL-Tg(APPSwFlLon, PSEN1∗ M146L∗L286V)6799Vas/
Mmjax (5XFAD Tg mice) were used for producing the focal
cerebral ischemia.
Experimental procedures involving the use of live animalsQ7
have been carried out in accordance with the guidelines
established by the European Community Directive 86/609/EEC
(November 24, 1986), Italian Ministry of Health and the
University of Turin institutional guidelines on animal welfare
(law 116/92 on Care and Protection of living animals undergoing
experimental or other scientific procedures; authorization
number 17/2010-B, June 30, 2010). Moreover, the Ethical
Q10
Committee of the University of Turin approved this type of
studies.
The animals were maintained under 12-h light/dark cycles
and were provided with water and food ‘‘ad libitum’’ (standard
mouse chow 4RF25-GLP, Mucedola srl, Settimo Milanese, Italy).
Specifically, all the procedures were carried out in order to
minimize the pain and distress in the animals and we used
the fewest number of animals required to obtain statistically
significant data.
Photothrombotic Focal Ischemia
Focal ischemia was performed as previously described (Labat-
gest and Tomasi, 2013). Briefly, 10 min before surgery,
the animals were i.p injected with Rose Bengal (15 mg/ml)
according to their body weight (10 µl/g). Then, we used 4%
isoflurane (Isoflurane-Vet 100%, Liquid, Merial Italy, Milan,
Italy) vaporized in O2/N2O 50:50 to anesthetize wt and tg
mice. The anesthesia was maintained at 1.5%–2.5% isoflurane
while mice were in the stereotaxic apparatus for small rodents
(Stoelting, Wood Dale, IL, USA). The skull was exposed and
an optical fiber cable (150 W) was placed in close contact with
a small region (approximately 30 mm2) 2 mm lateral to the
Bregma, corresponding to the sensory motor cortex (Vogt and
Paxinos, 2014). After 15 min of illumination the mice were
sutured and placed in a warm cage for recovery.
After 24 h the animals were killed by using an overdose
of anesthetic, the brains were collected and cut with a mouse
brain matrix in 1 mm coronal slices; brain extracts were
removed from lesioned and controlateral areas. Then the
samples were prepared for Triphenyl-Tetrazolium Chloride
(TTC) staining. The TTC staining was used to stain and
allow dissection of the lesioned areas and not to quantify
the amount of the ischemic damage. The TTC reaction was
stopped with 4% paraformaldehyde (PFA) in 0.1 M phosphate
buffer (PB, pH 7.4). The brain slices were maintained in
the fixative for 2 weeks and then processed for the isotropic
fractionator.
Isotropic Fractionator Method
Isotropic fractionator was executed according to Herculano-
Houzel and Lent (2005) following a TTC staining as described
before (Repetto et al., 2016). Briefly, after the neural tissue was
properly fixed, a single brain slice per animal was collocated
into a glass tissue grinder, a saline-detergent solution consisting
of 40 mM sodium citrate and 1% TritonTM X-100 (Sigma-
Aldrich, St. Louis, MO, USA) was added and the tissue was
carefully homogenizated to obtain a nuclear suspension. The
nuclear suspension obtained was stained with the fluorescent
DNA dye 4′-6-diamino-2-phenylindole dihydrochloride (DAPI;
DAPI, dilactate, D9564, Sigma-Aldrich, St. Louis, MO, USA).
Aliquots from the isotropic suspension were loaded into a
hemeocytometer (Neubauer chamber) and observed under
fluorescence microscopy (Nikon Eclipse 80i). The nuclei density
was evaluated by counting the number of nuclei within sectors of
the hemeocytometer coverslipped (1 mm2 area; 0.1 mm depth)
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of four aliquots for sample. To recognize the fraction of neuronal
nuclei among the total number of DAPI-stained nuclei, another
aliquot of the isotropic suspension was collected and stained with
mouse primary antibody for the neuronal nuclear protein NeuN
(MAB377, Chemicon, Single Oak Drive, Temecula, CA, USA,
1:200 in PBS, overnight incubation at room temperature (RT)).
Then, the nuclei were washed in saline and incubated at RT
for at least 2 h with the secondary Cy3 conjugated anti-mouse
donkey antibody (Chemicon, Single Oak Drive, Temecula, CA,
USA; 1:200 in PBS) and normal donkey serum (1:10; D9663,
Sigma-Aldrich, St. Louis, MO, USA). The non-neuronal cells
were obtained as the difference between the total number of cells
and the total number of neurons.
Expression and Purification of
Recombinant TAT Fusion Proteins
TAT-fused Uch-L1 was provided by Dr. Ottavio Arancio
(Professor at Columbia University), the construct was obtained
as described by Gong et al. (2006).
Briefly, TAT vectors were transformed into E. Coli BL21(DE3)
pLysS competent cells (Novagen), and the obtained colonies were
grown as 1 ml overnight cultures in Luria broth (LB) medium
(Sigma-Aldrich) with 100 mg ampicillin, in the presence of
100 mM IPTG. Then the cultures were transferred to 500 ml LB
ampicillin plus 200 mM IPTG to obtain large-scale preparations.
Fusion proteins were purified according to ProBond purification
system (Invitrogen).
VUch-L1 fusion proteins were i.p. injected into mice at
0.03 g/kg, 20 min before the Rose Bengal injection and surgery
procedure. After 6 or 12 h, mice were sacrificed and protein
extracts were prepared and examined as described below.
Antibodies and Immunoblot Analyses
The following antibodies were used for immunoblotting analyses:
BACE1 (Millipore, AB5940, 1:500), pJNK1/2 (Cell Signaling
Technology, #9251, 1:500); JNK1/2 (Cell Signaling Technology,
#9252, 1:500); BAX (Santa Cruz Biotechnology, Sc-493, 1:100);
Bcl-2 (Santa Cruz Biotechnology, Sc-509, 1:200); β actin (Sigma-
Aldrich, A5441, 1:5000); Uch-L1 (Santa Cruz Biotechnology
Sc-1183, 1:200).
Fresh frozen brains were homogenized in ice-cold buffer
consisting of 20 mM Tris-HCl pH7.4, 150 mM NaCl, 2 mM
EGTA, 1 mM EDTA, 1% TritonTM-X-100, 1 mM PMSF,
phosphatase and protease inhibitors and then centrifuged at
12,000 rpm for 20 min at 4◦C in order to obtain soluble proteins.
Lysates (20 µg) were run on 4%–12% Tris-HCl gradient PAGE
gel (Invitrogen) and then transferred to nitrocellulose blotting
membrane (GE Healthcare 10600008). Peroxidase-conjugated
secondary antibodies were incubated 1 h at RT and revealed with
Luminata ForteWestern substrate (WBLUF0100,Millipore). The
correct protein loading was controlled normalizing with β actin
antibody.
Evaluation of Aβ 42 Production by ELISA
Whole cell extracts were made in ice-cold lysis buffer
(PBS, TritonX-100, SDS 10%, DTT 1 M, PMSF 0.1% and
aprotinin) for 30 min and sonicated for 1 min. The lysates
were centrifugated at 17,860 g for 15 min to clarify the
suspensions. The protein concentration was quantified following
Bradford’s method (1976). The amount of Aβ 42 was evaluated
using the Human/Rat βAmyloid ELISA Kit (Wako Chemicals
GmbH, Neuss, Germany) according to the manufacturer’s
instructions.
BACE1 Activity
BACE-1 activity was measured using a commercially available
secretase kit from Calbiochem (Merck, Darmstadt, Germay),
according to the manufacturer’s protocol. Briefly, samples were
lysed in cold 1× Extraction Buffer (provided by the kit) to obtain
a final protein concentration of 1 mg/mL.
The method is based on the ability of the enzyme to cleave
a peptide conjugated with a reporter molecules (EDANS and
DABCYL). The cleavage induces the release of a fluorescent
signal that was detected using a fluorescence microplate reader
(excitation wavelength of 355 nm and emission 510 nm) and the
signal is proportional to the enzymatic activity. BACE1 activity
was expressed as percentage change over activity level of control
samples (Guglielmotto et al., 2012).
Hydrolase Activity Assay
The hydrolase activity assay was performed using the fluorogenic
ubiquitin-7-amino-4-methylcoumarin (ubiquitin-AMC; Boston
Biochem, Cambridge, MA, USA) substrate diluted in an assay
buffer (50 mM Tris–HCl pH 7.6, 0.5 mM EDTA, 5 mMDTT and
0.1 mg mL ovalbumin). The reaction mixture containing 400 nM
substrate and 100 µg protein samples was incubated for 5 min at
RT and the enzymatic activity was measured using a fluorescence
spectrometer (LS55; Perkin Elmer Instruments, Waltham, MA,
USA) at 25◦C (EX 380 nm and EM460 nm; Guglielmotto et al.,
2012).
NF-κB Activity
The activity of NF-κB was measured using a commercially
available kit (Active Motif, Rixensart, Belgium). The NF-κB
contained in the nuclear extracts specifically binds to an
oligonucleotide containing anNF-κB consensus binding site. The
primary antibodies recognize epitopes on p65, p50, p52, Rel B
and RelC proteins uponDNAbinding (Guglielmotto et al., 2012).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
version 4.0 (GraphPad software, San Diego). All values were
presented as mean ± standard error (SEM). Means were
compared by one or two-way analysis of variance (ANOVA) with
Bonferroni as a post hoc test (Manassero et al., 2016). Q12
RESULTS
The Uch-L1 Activity Decrease Is Common
Event in AD and VD
We performed all experiments in control or 5xFAD Tg mice
subjected or not to thrombotic focal cerebral ischemia mediated
by photo-activation with Rose Bengal and then sacrificed up
to 12 h later. Figure 1A reports the hydrolase activity; as
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FIGURE 1 |Q4
Q5
Ubiquitin C-terminal hydrolase L1 (Uch-L1) decrease mediates BACE1 up-regulation. (A) Hydrolase activity in control and Tg mice subjected or not to
Rose Bengal photo-activation and sacrificed 6 h later. Hydrolase activity was significantly decreased in control mice and further inhibited in Tg mice.
(B) Representative western blot of brain extracts from control and Tg mice subjected or not to Rose Bengal photo-activation using Uch-L1 antibody for detection.
β actin served as loading control. Densitometric quantification shows that Tg mice have slightly lower basal protein levels respect to controls but after thrombotic
ischemia the Uch-L1 levels are inhibited resulting significant not only in Tg controls but also respect to ischemic injured control mice. (C) Representative western blot
of brain extracts from control and Tg mice subjected or not to Rose Bengal photo-activation using BACE1 antibody for detection. β actin served as loading control.
Densitometric quantification shows that Tg mice have higher basal protein levels respect to controls but after thrombotic ischemia the BACE1 levels are increased
resulting significant not only in Tg controls but also respect to ischemic injured control mice. (D) BACE1 activity in control and Tg mice subjected or not to Rose
Bengal photo-activation. BACE1 activity was significantly increased in control mice and further enhanced in Tg mice. (E) Aβ 42 concentration in brain extracts of
control and Tg mice subjected or not to Rose Bengal photo-activation. The vascular injury in wild type mice was followed by a significant increase in Aβ 42 levels with
respect to controls. The basal levels of Aβ 42 in Tg mice were significantly higher than those of both control mice subjected or not to photothrombosis. The ischemic
injury in Tg mice was followed by a further significant production of Aβ 42. The data are mean ± standard error (SEM). ∗p < 0.05 vs. control mice; ∗∗p < 0.01 vs.
control mice; ◦p < 0.05 vs. control mice subjected to Rose Bengal photo-activation. N = 6.
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shown, the thrombotic ischemia in control mice was followed
by approximately 40% decrease of activity, whereas the ischemic
injury induced a drastic decrease (−70%) of hydrolase levels
in Tg mice that presented significant lower basal levels of the
enzyme (−30%).
To confirm the role of Uch-L1 in the decreased hydrolase
levels we performed western blot analysis using monoclonal
Uch-L1 antibody and we found a significant decrease in the
enzyme protein levels in both controls and Tgmice after ischemic
injury (Figure 1B). We previously reported that the decrease of
FIGURE 2 |Q4
Q5
Q11
NF-κB pathway is activated in control as well as Tg mice exposed to Rose Bengal photo-activation. The total NF-κB activation has been evaluated by
screening all members of NF-κB family. The ischemic injury was followed by a nuclear activation of p50 and p65, RelC in Tg mice. In control mice p50 did not seem
activated. The data are mean ± standard error (SEM). ∗p < 0.05 vs. control mice; ∗∗p < 0.01 vs. control mice; ◦p < 0.05 vs. control mice subjected to Rose Bengal
photo-activation. N = 6.
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Uch-L1 activity corresponded to an increase in BACE1 protein
levels (Guglielmotto et al., 2012). Here we confirmed that the
two events are related since the vascular injury was able to
significantly (approximately 2.5-fold) increase BACE1 protein
levels. Tgmice have higher basal protein levels respect to controls
(2-fold) but after thrombotic ischemia the BACE1 levels are
increased, resulting significant not only vs. Tg controls but also
respect to ischemic injured control mice (2-fold increase vs.
Tg controls and 3-fold increase vs. controls ischemic injured;
Figure 1C). To confirm that BACE1 was active, we measured
the enzymatic activity and we confirmed that vascular injury
increased BACE1 activity of 20% in control mice whereas in Tg
mice produced a 50% increase; the basal activity of BACE1 in
Tg mice was increased respect to control mice of approximately
25% (Figure 1D). We also measured levels of Aβ 42 in our
experimental models (Figure 1E). The vascular injury in wild
type mice was followed by a significant increase in Aβ 42 levels
respect to control animals in which the levels were almost
undetectable. As expected, the basal levels of Aβ 42 in Tg mice
were significantly higher than those of control mice subjected
or not to photothrombosis. The ischemic injury in Tg mice
was followed by a further significant production of Aβ 42
(Figure 1D).
Thus, we observed that the decrease in Uch-L1 determined an
increase of BACE1 protein levels and activity and an increased
production of Aβ 42. Moreover, we can affirm that the decrease
of Uch-L1 is a common event in AD and VD and that when both
pathologies are present there is a cumulative effect.
The Decrease of Uch-L1 Depends on the
Induction of NF-κB
We studied this pathway because it had been previously reported
that Aβ 42 regulates BACE1 promoter transactivation and
activity through NF-κB pathway (Buggia-Prevot et al., 2008)
and that the activation of this pathway abolishes Uch-L1 gene
transcription (Wang et al., 2011). We also previously found
that the pharmacological inhibition of NF-κB by blocking the
nuclear translocation of p50 or p65 in an in vitro model was
followed by a completely protection of the Uch-L1 decrease
as well as of the BACE1 increase (Guglielmotto et al., 2012).
Thus, we investigated whether the focal ischemia could activate
NF-κB in our experimental model. We demonstrated that the
ischemic injury was able to induce nuclear activation of total NF-
κB obtained by screening all NF-κB family members (Figure 2)
in control mice and Tg mice exposed to Rose Bengal photo-
activation. The results suggest that this pathway could be
responsible for the decrease of Uch-L1.
The Decrease of Uch-L1 Is Followed by
Necrotic and Apoptotic Cell Death
We evaluated the neuronal density after lesion and we found
that there was a significant decrease in control and Tg mice
exposed to Rose Bengal photo-activation respect to not lesioned
mice (Figure 3A). To determine the amount of apoptotic cell
death we measured the protein levels of the proapoptotic effector
BAX as well as the antiapoptotic protein Bcl-2. As reported in
Figures 3B,C, the focal ischemia caused a significant increase
FIGURE 3 | Q4
Q5
Q10
The decrease of Uch-L1 was followed by cell death. (A) The
neuronal density after lesion was significantly decreased in control and Tg
mice exposed to Rose Bengal photo-activation respect to not lesioned mice.
(B) Representative western blot of brain extracts from control and Tg mice
subjected or not to Rose Bengal photo-activation using Bax and Bcl-2
antibodies. β actin served as loading control. Densitometric quantification
shows that the ischemic injury caused a significant increase of BAX protein
and a parallel significant decrease of Bcl-2 in control mice. The ischemic injury
induced in Tg mice was followed by a further increase in Bax and decrease in
Bcl-2 levels, that resulted significant respect to lesioned control mice. The
data are mean ± standard error (SEM). ∗p < 0.05 vs. control mice;
∗∗p < 0.01 vs. control mice; ∗∗∗p < 0.01 vs. control mice; ◦p < 0.05 vs.
control mice subjected to Rose Bengal photo-activation. N = 6.
of BAX protein (2-fold) and a parallel significant decrease in
Bcl-2 (40%) in control mice. The ischemic injury induced in Tg
mice was followed by a further increase in Bax (3.5-fold) and
decrease in Bcl-2 (−60%) levels, that resulted significant respect
to lesioned control mice (Figures 3B,C).
Restoration of Uch-L1 Corrects the
BACE1 Induction and Prevents Cell Death
To foster the levels of Uch-L1 we injected control and Tg
mice with a fusion protein between transduction domain of the
HIV-transactivator protein (TAT), fused with an HA tag, and
Uch-L1 (TAT-HA-Uch-L1; Gong et al., 2006) 30 min before
ischemic injury.
To evaluate if the peptide was able to cross the blood brain
barrier we performed a western blot using HA antibody, thus
HA is attached to the peptide. A band is visible in cerebral
homogenates after treatment with Uch-L1 peptide (data not
shown). As reported in Figure 4A, the injection of TAT-
HA-Uch-L1 restored normal Uch-L1 activity both in control
and in Tg mice exposed to photoischemic injury (Figure 4A).
The restoration of Uch-L1 was able to completely prevent
the increase of BACE1 protein levels both in control and Tg
mice at 6 h post injury, as reported by the representative
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FIGURE 4 |Q4
Q5
Uch-L1 restoration counteracts the BACE1 up-regulation.
(A) Hydrolase activity in control and Tg mice subjected or not to Rose Bengal
photo-activation and sacrificed 6 h later. The injection of TAT-HA-Uch-L1
re-established normal hydrolase activity both in control as well as in Tg mice
exposed to photoischemic injury. (B) Representative western blot of brain
extracts from control and Tg mice subjected or not to Rose Bengal
photo-activation using BACE1 antibody for detection. β actin served as
loading control. Densitometric quantification shows that the restoration of
Uch-L1 was able to completely prevent the increase of BACE1 protein levels
both in control and Tg mice at 6 h post injury. The data are mean ± standard
error (SEM). ∗p < 0.05 vs. control mice; ∗∗p < 0.01 vs. control mice;
◦p < 0.05 vs. control mice subjected to Rose Bengal photo-activation. N = 6.
blot and by the densitometric analysis (Figure 4B). Finally,
we also found that pre-treatment with TAT-HA-Uch-L1 was
able to protect against the neuronal cell death, indeed we
found that the restoration of Uch-L1 significantly increases
the percentage of neuronal density in pre-lesioned Tg treated
animals respect to untreated lesioned ones (Figure 5A). Finally,
we found that the restoration of Uch-L1 rescues Bax control
levels (Figure 5B) and protects the decrease Bcl-2, both in
controls and Tg mice.
DISCUSSION
The ‘‘vascular hypothesis of AD’’ is supported by studies showing
that vascular pathology leads to inability of Aβ clearance
from the brain, producing Aβ accumulation in parenchyma
and blood vessels (Canobbio et al., 2015; Janota et al., 2016).Q13
Vascular pathology includes macroinfarcts and microinfarcts,
atherosclerosis as well as cerebral amyloid angiopathy.
FIGURE 5 | Q4
Q5
Uch-L1 restoration protects cell death. (A) The restoration of
Uch-L1 exerts a positive effect on neuronal density in pre-lesioned Tg treated
animals respect to untreated lesioned ones. (B) Representative western blot of
brain extracts from control and Tg mice subjected or not to Rose Bengal
photo-activation and pre-treated or not with TAT-HA-Uch-L1 using Bax and
Bcl-2 antibodies. β actin served as loading control. Densitometric
quantification shows that the restoration of Uch-L1 almost completely prevent
the release of pro-apoptotic Bax and the decrease of anti-apoptotic Bcl-2
proteins, both in controls and Tg mice. The data are mean ± standard error
(SEM). ∗∗p < 0.01 vs. control mice; ◦p < 0.02 vs. Rose Bengal; #p < 0.05
Uch-L1p vs. Uch-L1p + Rose Bengal. N = 6.
Several studies show vascular pathology in 50% of the elderly
population and confirm that the simultaneous presence of
vascular and AD lesions is closely related to the severity of
dementia (Schneider, 2009; Attems and Jellinger, 2014).
Furthermore, the co-existence of vascular damage and AD
appears to be an important condition in determining a further
and significant decrease in cognitive capacity with respect to
subjects with AD alone (Schneider and Bennett, 2010). Some
authors suggested that vascular contribution in AD is much
broader that the tissue injury seen in pathologic and imaging
studies. Thus, vessel disease and vascular injury are associated
with AD but their role in the development of the disease remains
unclear.
In this work we found that the focal ischemicmicroinfarctions
induced by laser excitation of the photosensitive dye Bengal
Rose determined the decrease of Uch-L1 as well as BACE1 over-
expression. We previously demonstrated that Aβ 42 decreased
the activity of Uch-L1 by activating NF-κB pathway and that this
event up-regulated BACE1 (Guglielmotto et al., 2012). It has been
reported that NF-κB pathway transactivates BACE1 promoter
(Buggia-Prevot et al., 2008) and concomitantly down-regulates
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Uch-L1 expression (Wang et al., 2011). Thus, we suggest that,
also in this experimental model, the decrease of Uch-L1 and
the increase of BACE1 are mediated by NF-κB pathway. Other
authors found a down-regulation of Uch-L1 in the hippocampus
of AD brain. It has been found that Aβ may down-regulate
Uch-L1 in the AD brain, which in turn impairs BDNF/TrkB-
mediated retrograde signaling, compromising synaptic plasticity
and neuronal survival (Poon et al., 2013). Moreover, a recent
study by Öhrfelt et al. (2016) first assessed the potential role ofQ13
Uch-L1 as a CSF biomarker for AD. Thus, CSF Uch-L1 seems
to correlate with CSF total and phospho Tau. Large literature
data support the notion that inflammation plays a crucial role
in mediating vascular complications and dysfunctions (Ross,
1999; Charo and Taubman, 2004; Hansson and Libby, 2006).
Recently, the pro-inflammatory cytokine TNFα has been found
a prominent factor in the pathogenesis of vascular diseases
(McKellar et al., 2009) and it has been observed that NF-κB
cascade is a crucial component of TNFα signal transduction
(Bradley, 2008).
In this context, Ichikawa et al. (2010) reported that an
up-regulation of Uch-L1 mediates a negative feedback to
TNF-α mediated vascular inflammation. Uch-L1 was also
found expressed in both human endothelial cells and vascular
smooth muscle cells and data obtained by Takami et al.
(2007) suggested that Uch-L1 may partially attenuate vascular
remodeling through the down-regulation of NF-κB pathway.
Specifically, Uch-L1 decreased the NF-κB activity induced
by TNF-α and increased eNOS expression, which was able
to protect atherosclerosis reducing ischemic vascular disease
(Takami et al., 2007). Additionally, the release of prostaglandins,
such as biologically active cyclopentenone prostaglandins, that
are massively produced in the rat brain after temporary focal
ischemia, selectively blocks Uch-L1 activity (Liu et al., 2011).
Our current and previous data (Guglielmotto et al., 2012) suggest
that the decrease of Uch-L1 is part of a loop that potentiates
Aβ accumulation in vascular injury and that the restoration of
Uch-L1 activity could represent a novel therapeutic strategy for
AD and vascular dementia.
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